Entries by Maren Kühr

Moss Cell Line Finds Broader Application

Freiburg-based Eleva relies on its moss-based platform for the development of new biologics both independently and with partners. A new alliance with Spanish CDMO 3PBIOVIAN now secures clinical production capacity for both activities.

Connecting Europe’s biotech community

Join YEBN’s top biotech event in Budapest! Connect with innovators, learn from professionals, and shape the future of biotech. Don’t miss this opportunity to network and grow, join us now!

Life Sciences Meets Lab Automation

SLAS is pleased to bring together the laboratory automation and life sciences research communities at the SLAS Europe 2025 Conference & Exhibition at the Congress Center Hamburg, 20-22 May.

Boosting Startup Ecosystems

The Technologiepark Heidelberg has been shaping ­Heidelberg‘s startup ecosystem with 100,000 sqm of lab and office spaces, individual startup support, and top events for over 40 years – offering ideal ­conditions for established companys and startups in the fields of life sciences, biotech, industry tech, and AI.

Enhancing macromolecule drug discovery with CDD

The landscape of macromolecule drug discovery is evolving rapidly, with oligonucleotides and peptides leading the way in innovative therapeutic applications. CDD Vault, a leading scientific data management system, significantly improves the way researchers manage macromolecule data by introducing a dedicated Macromolecule mode that seamlessly integrates with modern workflows.

European biotechs navigating a new financing environment

After the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging long-term financing trends as well as the recent events in the US, which may also impact the biotech industry.

Trump’s win will affect the biotechnology sector

During the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?

The golden age of engineered therapeutic antibodies

Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.